地塞米松介导的Notch信号抑制阻断白血病细胞与间充质基质细胞的相互作用
研究比较白血病来源与健康供者骨髓间充质干细胞(MSC)的功能差异,发现Notch信号在白血病MSC中促进AML细胞增殖;地塞米松抑制白血病MSC的Notch信号并减少AML细胞增殖,在体内减少白血病MSC数量并改善白血病小鼠生存。
要点
- 白血病MSC与健康供者MSC存在功能差异,直接接触是影响AML细胞增殖的必要条件。
- 白血病MSC中Notch表达及激活促进AML细胞增殖,过表达Notch胞内域(Notch ICN)增强该效应。
- 地塞米松抑制白血病MSC的Notch信号并减少AML细胞增殖,体内改善白血病小鼠生存。
核心结论
- 靶向白血病细胞与AML MSC的相互作用(使用地塞米松或Notch抑制剂)可能进一步改善AML患者的治疗结局。
研究设计与样本
- 研究比较白血病来源(AML MSC)与健康供者来源(HD MSC)骨髓间充质干细胞的功能差异,并检测Notch信号及地塞米松、Notch抑制剂的作用。
主要发现
- 白血病细胞与AML MSC的直接相互作用是影响AML细胞增殖的必要条件。
- AML MSC中Notch表达及激活增强AML细胞增殖,过表达Notch胞内域(Notch ICN)增强AML细胞增殖。
- 地塞米松处理抑制AML MSC的Notch信号,导致AML细胞增殖减少。
- Notch抑制剂对单独白血病细胞仅 marginal 效应,但强烈影响AML MSC的Notch信号并消除其对AML细胞的细胞保护功能。
- 体内地塞米松处理抑制AML MSC的Notch信号,减少AML MSC数量并改善白血病小鼠生存。
临床怎么用
- 作者认为,使用地塞米松或Notch抑制剂靶向白血病细胞与AML MSC的相互作用可能进一步改善AML患者的治疗结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukaemia (AML) is a haematological malignancy characterized by a poor prognosis. Bone marrow mesenchymal stromal cells (BM MSCs) support leukaemic cells in preventing chemotherapy-induced apoptosis. This encouraged us to investigate leukaemia-BM niche-associated signalling and to identify signalling cascades supporting the interaction of leukaemic cells and BM MSC. Our study demonstrated functional differences between MSCs originating from leukaemic (AML MSCs) and healthy donors (HD MSCs). The direct interaction of leukaemic and AML MSCs was indispensable in influencing AML cell proliferation. We further identified an important role for Notch expression and its activation in AML MSCs contributing to the enhanced proliferation of AML cells. Supporting this observation, overexpression of the intracellular Notch domain (Notch ICN) in AML MSCs enhanced AML cells' proliferation. From a therapeutic point of view, dexamethasone treatment impeded Notch signalling in AML MSCs resulting in reduced AML cell proliferation. Concurrent with our data, Notch inhibitors had only a marginal effect on leukaemic cells alone but strongly influenced Notch signalling in AML MSCs and abrogated their cytoprotective function on AML cells. In vivo, dexamethasone treatment impeded Notch signalling in AML MSCs leading to a reduced number of AML MSCs and improved survival of leukaemic mice. In summary, targeting the interaction of leukaemic cells and AML MSCs using dexamethasone or Notch inhibitors might further improve treatment outcomes in AML patients.
引用
- Ahmed HMM, Nimmagadda SC, Al-Matary YS, et al. Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells. Br J Haematol. 2021. PMID: 34792186. doi:10.1111/bjh.17940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。